Please assess the completion status of the following clinical trial:

Trial Title: A Degarelix Trial in Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has given written consent prior to any trial-related activity is performed. (A trial-related activity is defined as any procedure that would not have been performed during the normal management of the patient).~* Has completed the CS35 trial.~Exclusion Criteria:~* Has been withdrawn from the CS35 trial.~* Has had end of trial visit in CS35 prior to approval of the CS35A protocol.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Degarelix 240 mg/480 mg (Type: EXPERIMENTAL): None
- Goserelin acetate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).